Samlyn Capital LLC Sells 536,633 Shares of Natera, Inc. (NASDAQ:NTRA)

Samlyn Capital LLC reduced its position in shares of Natera, Inc. (NASDAQ:NTRA) by 27.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,447,946 shares of the medical research company’s stock after selling 536,633 shares during the quarter. Natera accounts for 2.6% of Samlyn Capital LLC’s investment portfolio, making the stock its 8th biggest holding. Samlyn Capital LLC owned about 1.18% of Natera worth $156,798,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in NTRA. Itau Unibanco Holding S.A. purchased a new position in shares of Natera during the 2nd quarter valued at $28,000. Principal Securities Inc. purchased a new position in shares of Natera during the 4th quarter valued at $32,000. GAMMA Investing LLC grew its holdings in shares of Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 108 shares in the last quarter. YHB Investment Advisors Inc. purchased a new position in shares of Natera during the 1st quarter valued at $36,000. Finally, Tobam purchased a new position in shares of Natera during the 2nd quarter valued at $74,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Jonathan Sheena sold 2,700 shares of Natera stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $127.57, for a total transaction of $344,439.00. Following the transaction, the insider now directly owns 284,741 shares of the company’s stock, valued at $36,324,409.37. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Steven Leonard Chapman sold 5,024 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52. Following the transaction, the chief executive officer now directly owns 195,686 shares in the company, valued at approximately $25,141,737.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jonathan Sheena sold 2,700 shares of the business’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $127.57, for a total transaction of $344,439.00. Following the transaction, the insider now owns 284,741 shares in the company, valued at $36,324,409.37. The disclosure for this sale can be found here. In the last 90 days, insiders sold 93,921 shares of company stock valued at $10,551,281. Company insiders own 7.60% of the company’s stock.

Analysts Set New Price Targets

NTRA has been the topic of several research analyst reports. TD Cowen boosted their price target on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a report on Friday, August 9th. Morgan Stanley upped their price objective on shares of Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. Robert W. Baird upped their price objective on shares of Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Piper Sandler reiterated an “overweight” rating and issued a $150.00 price objective on shares of Natera in a report on Friday, September 13th. Finally, Canaccord Genuity Group upped their price objective on shares of Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, August 27th. One analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and a consensus price target of $120.07.

Natera Stock Down 3.3 %

NASDAQ NTRA opened at $123.54 on Tuesday. The stock has a market cap of $15.17 billion, a PE ratio of -39.60 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $132.01. The firm has a 50-day simple moving average of $114.66 and a 200 day simple moving average of $105.76.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.39. The company had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company’s revenue was up 58.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.97) earnings per share. On average, research analysts forecast that Natera, Inc. will post -1.96 EPS for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.